• 1
    Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 71722.
  • 2
    Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25: 3303.
  • 3
    Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterol 1975; 69: 969.
  • 4
    Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992; 305: 202.
  • 5
    Michetti P, Peppercorn MA. Medical therapy of specific clinical presentations. Gastroenterol Clin North Am 1999; 28: 35370.
  • 6
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 2159.
  • 7
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterol 2000; 118: 101824.
  • 8
    Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 32939.
  • 9
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterol 2000; 118: 70513.
  • 10
    Achkar JP, Stevens T, Brzezinski A, et al. 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy. Am J Gastroenterol 2000; 95: 2491(Abstract).
    Direct Link:
  • 11
    Seidman EG, Dubinsky M, Patriquin H, et al. Recent developments in the diagnosis and management of paediatric inflammatory bowel disease. In: Williams, CN, Bursey, RF, Gall, DG, et al., eds. Trends in Inflammatory Bowel Disease Therapy 1999. Doredrecht: Kluwer Academic Publishers, 2000: 8795.
  • 12
    Cuffari C, Sharma S. 6-MP metabolite levels tailored to achieve clinical responsiveness in pediatric Crohn's disease. Gastroenterol 1999; 116: A771(Abstract).
  • 13
    Dubinsky MC, Hassard PV, Abreu MT, et al. Thioguanine (6-TG): a therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP). Gastroenterol 2000; 118: A891(Abstract).
  • 14
    Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 4016.
  • 15
    Cuffari C, Seidman G, Latour S, et al. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol 1996; 74: 5805.
  • 16
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogeneic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 65162.
  • 17
    Dubinsky M, Lamothe S, Sinnet D, et al. 6-MP metabolite levels predict clinical efficacy and drug toxicity in pediatric IBD. J Pediatr Gastroenterol 1998; 27: 465(Abstract).
  • 18
    Markowitz J, Grancher K, Kohn N. Monitoring 6MP metabolites in clinical practice. J Pediatr Gastroenterol 2000; 31: S80(Abstract).
  • 19
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.
  • 20
    Dubinsky MC, Hassard PV, Kam LY, et al. Serial 6-mercaptopurine measurements in combination with dose escalation unmasks an important biochemical explanation for ‘6-MP resistance’. Gastroenterol 2000; 118: A890(Abstract).
  • 21
    Corominas H, Domenech M, Gonzalez D, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000; 95: 23137.
    Direct Link:
  • 22
    Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterol 2000; 118: 102530.